1.
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
by Xie, Xinfang, MD
The Lancet (British edition), 2016, Vol.387 (10017), p.435-443
2.
Interpretation of the evidence for the efficacy and safety of statin therapy
by Collins, Rory, Prof
The Lancet (British edition), 2016, Vol.388 (10059), p.2532-2561
3.
Polypills for the prevention of cardiovascular disease: a framework for wider use
by Patel, Anushka
Nature medicine, 2022-02, Vol.28 (2), p.226-229
4.
Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials
by Collins, Rory
The Lancet (British edition), 2001, Vol.357 (9253), p.373-380
5.
Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies
by MacMahon, Stephen
The Lancet (British edition), 2001-02-10, Vol.357 (9254), p.455-462
6.
Major surgery in south India: a retrospective audit of hospital claim data from a large community health insurance programme
by Shaikh, Maaz, MPH
The Lancet (British edition), 2015, Vol.385, p.S23-S23
7.
Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial
by Arima, Hisatomi
Journal of neurology, neurosurgery and psychiatry, 2014-11, Vol.85 (11), p.1284-1285
8.
Responding to China's hypertensive crisis
by MacMahon, Stephen
The Lancet (British edition), 2009, Vol.374 (9703), p.1728-1729
9.
Blood-pressure-related disease is a global health priority
by MacMahon, Stephen
American journal of hypertension, 2008, Vol.371 (9623), p.1480-1482
10.
Rationale and design of the Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS): A factorial, cluster-randomized trial of 2 practical cardiovascular disease prevention s...
by Chow, Clara K., MBBS, FRACP, PhD
The American heart journal, 2009, Vol.158 (3), p.349-355
11.
Prediction of Heart Failure by Amino Terminal-pro–B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease
by Campbell, Duncan J
Hypertension (Dallas, Tex. 1979), 2005-01, Vol.45 (1), p.69-74
12.
The Burden of Blood Pressure-Related Disease: A Neglected Priority for Global Health
by Perkovic, Vlado
Hypertension (Dallas, Tex. 1979), 2007-12, Vol.50 (6), p.991-997
13.
Differences between blood-pressure-lowering drugs
by MacMahon, Stephen
The Lancet (British edition), 2000, Vol.356 (9227), p.352-353
14.
Blood-pressure-related disease is a global health priority
by MacMahon, Stephen
American journal of hypertension, 2008-08, Vol.21 (8), p.843
15.
Blood-Pressure-Related Disease Is a Global Health Priority
by MacMahon, Stephen
American journal of hypertension, 2008-08, Vol.21 (8), p.843-844
16.
Leg ulceration and perceived health: a population based case-control study
by Jull, Andrew
Age and ageing, 2004-05, Vol.33 (3), p.236-241
17.
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
by Sundström, Johan
The Lancet (British edition), 2014-08-16, Vol.384 (9943), p.591-598
18.
An Economic Evaluation of a Perindopril-Based Blood Pressure Lowering Regimen for Patients Who Have Suffered a Cerebrovascular Event
by Tavakoli, Manouchehr
The European journal of health economics, 2009-02-01, Vol.10 (1), p.111-119
19.
Association of Environmental Tobacco Smoke Exposure with Socioeconomic Status in a Population of 7725 New Zealanders
by Whitlock, G
Tobacco control, 1998-10-01, Vol.7 (3), p.276-280
20.
Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury—outcomes at 6 months
by Edwards, Phil
The Lancet (British edition), 2005, Vol.365 (9475), p.1957-1959
